Development and characterization of CD22-targeted pegylated-liposomal doxorubicin (IL-PLD)

Investigational New Drugs

Volumn 28, Issue 3, 2010, Pages 260-267

  O'Donnell, Robert T ^a,b   Martin, Shiloh M ^a   Ma, Yunpeng ^a   Zamboni, William C ^c,d   Tuscano, Joseph M ^a,b,e  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b VETERANS AFFAIRS MEDICAL CENTER   (United States)

^c University of North Carolina   (United States)

^d UNIVERSITY OF NORTH CAROLINA   (United States)

^e UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

CD22; Doxorubicin; HB22.7; Liposomes; Non Hodgkin's lymphoma

Indexed keywords

CD22 ANTIGEN; DOXORUBICIN; IMMUNOLIPOSOME;

ARTICLE; CONTROLLED STUDY; DRUG ACCUMULATION; DRUG CYTOTOXICITY; DRUG TARGETING; HUMAN; HUMAN CELL; IC 50; IMMUNOFLUORESCENCE; LEUKEMIA CELL LINE; NONHODGKIN LYMPHOMA; PRIORITY JOURNAL; RAJI CELL;

ANTIBODIES, MONOCLONAL; ANTIGENS, CD22; ANTINEOPLASTIC AGENTS; CELL LINE, TUMOR; CYTOTOXICITY TESTS, IMMUNOLOGIC; DOXORUBICIN; DRUG COMPOUNDING; DRUG DELIVERY SYSTEMS; HUMANS; IMMUNOTOXINS; LYMPHOMA, NON-HODGKIN; POLYETHYLENE GLYCOLS;

EID: 77952241780     PISSN: 01676997     EISSN: None     Source Type: Journal    
DOI: 10.1007/s10637-009-9243-7     Document Type: Article

References (25)

1. Schumer ST, Joyce RM (2003) Radioimmunotherapy for Non-Hodgkin's Lymphoma. Progress in Oncology 46-72
2. Ries L, Melbert D, Krapcho M, Stinchcomb D, Howlader N, Horner M, Mariotto A, Miller B, Feuer E, Altekruse S, Lewis D, Clegg L, Eisner M, Reichman M, Edwards BE (2008) SEER cancer statistics review, 1975-2005. National Cancer Institute, Bethesda, MD
3. GN Hortobagyi 1997 Anthracyclines in the treatment of cancer. An overview Drugs 54 Suppl 4 1 7 10.2165/00003495-199754010-00001 10.2165/00003495- 199700544-00003 1:CAS:528:DyaK2sXntlygu7w%3D 9361955
4. SS Legha RS Benjamin B Mackay M Ewer S Wallace M Valdivieso SL Rasmussen GR Blumenschein EJ Freireich 1982 Reduction of doxorubicin cardiotoxicity by prolonged continuous intravenous infusion Ann Intern Med 96 133 139 1:STN:280:DyaL387jtlentg%3D%3D 7059060
5. EJ Gralla RW Fleischman YK Luthra SW Stadnicki 1979 The dosing schedule dependent toxicities of adriamycin in beagle dogs and rhesus monkeys Toxicology 13 263 273 1:CAS:528:DyaL3cXltF2quw%3D%3D 118548
6. BM Henderson WJ Dougherty VC James LP Tilley JF Noble 1982 Safety assessment of a new anticancer compound, mitoxantrone, in beagle dogs: comparison with doxorubicin. I. Clinical observations Cancer Treat Rep 66 1139 1143 1:CAS:528:DyaL38XitFSmt74%3D 7083216
7. DW Northfelt FJ Martin P Working PA Volberding J Russell M Newman MA Amantea LD Kaplan 1996 Doxorubicin encapsulated in liposomes containing surface-bound polyethylene glycol: pharmacokinetics, tumor localization, and safety in patients with AIDS-related Kaposi's sarcoma J Clin Pharmacol 36 55 63 1:CAS:528:DyaK28Xhs1egt7s%3D 8932544
8. H Maeda T Sawa T Konno 2001 Mechanism of tumor-targeted delivery of macromolecular drugs, including the EPR effect in solid tumor and clinical overview of the prototype polymeric drug SMANCS J Control Release 74 47 61 10.1016/S0168-3659(01) 00309-1 10.1016/S0168-3659(01)00309-1 1:CAS:528:DC%2BD3MXlslansrw%3D 11489482
9. A Gabizon F Martin 1997 Polyethylene glycol-coated (pegylated) liposomal doxorubicin. Rationale for use in solid tumours Drugs 54 Suppl 4 15 21 10.2165/00003495-199700544-00005 1:CAS:528:DyaK2sXntlygu7o%3D 9361957
10. Z Symon A Peyser D Tzemach O Lyass E Sucher E Shezen A Gabizon 1999 Selective delivery of doxorubicin to patients with breast carcinoma metastases by stealth liposomes Cancer 86 72 78 10.1002/(SICI) 1097-0142(19990701) 86:1<72::AID-CNCR12>3.0.CO;2-1 10.1002/(SICI)1097-0142(19990701) 86:1<72::AID-CNCR12>3.0.CO;2-1 1:CAS:528:DyaK1MXktleqtLc%3D 10391566
11. TM Allen DR Mumbengegwi GJ Charrois 2005 Anti-CD19-targeted liposomal doxorubicin improves the therapeutic efficacy in murine B-cell lymphoma and ameliorates the toxicity of liposomes with varying drug release rates Clin Cancer Res 11 3567 3573 10.1158/1078-0432.CCR-04-2517 10.1158/1078-0432.CCR-04- 2517 1:CAS:528:DC%2BD2MXjslOqtbo%3D 15867261 (Pubitemid 40627913)
12. P Sapra TM Allen 2004 Improved outcome when B-cell lymphoma is treated with combinations of immunoliposomal anticancer drugs targeted to both the CD19 and CD20 epitopes Clin Cancer Res 10 2530 2537 10.1158/1078-0432.CCR-03-0376 10.1158/1078-0432.CCR-03-0376 1:CAS:528:DC%2BD2cXivFSqsbs%3D 15073133 (Pubitemid 38445715)
13. TF Tedder J Tuscano S Sato JH Kehrl 1997 CD22, a B lymphocyte-specific adhesion molecule that regulates antigen receptor signaling Annu Rev Immunol 15 481 504 10.1146/annurev.immunol.15.1.481 10.1146/annurev.immunol.15.1.481 1:CAS:528:DyaK2sXisVCmt7s%3D 9143697 (Pubitemid 27169290)
14. S Sato JM Tuscano M Inaoki TF Tedder 1998 CD22 negatively and positively regulates signal transduction through the B lymphocyte antigen receptor Semin Immunol 10 287 297 10.1006/smim.1998.0121 10.1006/smim.1998.0121 1:CAS:528:DyaK1cXltlCiurw%3D 9695185 (Pubitemid 28375304)
15. JM Tuscano A Riva SN Toscano TF Tedder JH Kehrl 1999 CD22 cross-linking generates B-cell antigen receptor-independent signals that activate the JNK/SAPK signaling cascade Blood 94 1382 1392 1:CAS:528:DyaK1MXlt1Oksrk%3D 10438726
16. Tuscano JM, O'Donnell RT, Miers LA, Kroger LA, Kukis DL, Lamborn KR, Tedder TF, DeNardo GL (2003) Anti-CD22 ligand-blocking antibody HB22.7 has independent lymphomacidal properties and augments the efficacy of 90Y-DOTA-peptide-Lym-1 in lymphoma xenografts. Blood 101:3641-3647. doi: 10.1182/blood-2002-08-2629 (Pubitemid 36857954)
17. J Tuscano P Engel TF Tedder JH Kehrl 1996 Engagement of the adhesion receptor CD22 triggers a potent stimulatory signal for B cells and blocking CD22/CD22L interactions impairs T-cell proliferation Blood 87 4723 4730 1:CAS:528:DyaK28Xjt1equ7c%3D 8639842 (Pubitemid 26162372)
18. T Sakakibara FA Chen H Kida K Kunieda RE Cuenca FJ Martin RB Bankert 1996 Doxorubicin encapsulated in sterically stabilized liposomes is superior to free drug or drug-containing conventional liposomes at suppressing growth and metastases of human lung tumor xenografts Cancer Res 56 3743 3746 1:CAS:528:DyaK28XltVKks7Y%3D 8706018
19. T Ishida DL Iden TM Allen 1999 A combinatorial approach to producing sterically stabilized (Stealth) immunoliposomal drugs FEBS Lett 460 129 133 10.1016/S0014-5793(99) 01320-4 10.1016/S0014-5793(99)01320-4 1:CAS:528:DyaK1MXns1arsL8%3D 10571074
20. C Fiske Y Subbarow 1925 The colorimetric determination of phosphorus J Biol Chem 66 375 400 1:CAS:528:DyaB28XoslGn
21. SA Abraham DN Waterhouse LD Mayer PR Cullis TD Madden MB Bally 2005 The liposomal formulation of doxorubicin Methods Enzymol 391 71 97 10.1016/S0076-6879(05) 91004-5 10.1016/S0076-6879(05)91004-5 1:CAS:528:DC%2BD2MXltFCrt7Y%3D 15721375
22. P Sapra TM Allen 2002 Internalizing antibodies are necessary for improved therapeutic efficacy of antibody-targeted liposomal drugs Cancer Res 62 7190 7194 1:CAS:528:DC%2BD3sXhtVyrtQ%3D%3D 12499256
23. KM Haas S Sen IG Sanford AS Miller JC Poe TF Tedder 2006 CD22 ligand binding regulates normal and malignant B lymphocyte survival in vivo J Immunol 177 3063 3073 1:CAS:528:DC%2BD28Xot1CjsLc%3D 16920943
24. X Du R Beers DJ Fitzgerald I Pastan 2008 Differential cellular internalization of anti-CD19 and -CD22 immunotoxins results in different cytotoxic activity Cancer Res 68 6300 6305 10.1158/0008-5472.CAN-08-0461 10.1158/0008-5472.CAN-08-0461 1:CAS:528:DC%2BD1cXpt1WjsLg%3D 18676854
25. R Soloman AA Gabizon 2008 Clinical pharmacology of liposomal anthracyclines: focus on pegylated liposomal Doxorubicin Clin Lymphoma Myeloma 8 21 32 10.3816/CLM.2008.n.001 10.3816/CLM.2008.n.001 18501085 (Pubitemid 351449716)